#FDA approval

Balversa led to tumor regression in about a third of patients with susceptible genetic mutations.

Ibrance appears safe and effective for men in real-world use.

Progression-free and overall survival improved in patients treated with Tecentriq plus chemotherapy.

Cabometyx is the third liver cancer drug approved in the past six months.

Imbruvica plus Gazyva is the first chemotherapy-free regimen for chronic lymphocytic leukemia.

Atezolizumab plus chemotherapy delays disease progression in people with metastatic triple-negative breast cancer.

Tecentriq plus Abraxane was approved under accelerated approval based on progression-free survival.

HannaH trial demonstrated that Herceptin Hylecta was comparable to intravenous trastuzumab.

Median overall survival was 5.7 months for patients receiving Lonsurf and 3.6 months for those receiving placebo.

Patients receiving pembrolizumab experienced fewer recurrences or deaths.

The accelerated approval pathway facilitates earlier approval of drugs that treat serious conditions.

Cabometyx is the third liver cancer drug approved in the past six months.

Median progression-free survival 5.2 months in cabozantinib arm versus 1.9 months in placebo arms.

Four out of 10 FDA workers are sidelined.

Asparlas approved for children and young adults with acute lymphoblastic leukemia.

Elzonris approved for bone marrow disease that can evolve into leukemia.